The primary objective of this Phase IIa trial is to determine the effective doses and treatment period for an upcoming RX-10100 Phase IIb trial in subjects with erectile dysfunction (ED). The secondary objectives of this trial are to evaluate the safety and the quality of life in subjects with ED receiving RX-10100 treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
40
Placebo (w/o API)
5 mg/dose of RX-10100
10 mg/dose of RX-10100
Unnamed facility
Greenbelt, Maryland, United States
Unnamed facility
Woodlane, New Jersey, United States
Unnamed facility
Greer, South Carolina, United States
Scores on IIEF-EF Questionnaires and on SEP Questions II and III
Time frame: Weeks 4 and 8
Scores on other domains of IIEF, other questions on Subject Diaries, RigiScan measurement, and ED-QoL questionnaires
Time frame: Weeks 4 and 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
15 mg/dose of RX-10100